Editorial
Cofactors Involved in the Antiphospholipid Syndrome Cofactor involvement in the expression of lupus anticoagulant has been reported occasionally. In 1959 Loeliger presented evidence that prothrombin was required as a cofactor of the circulating anticoagulant in systemic lupus erythematosus'. Six years later Yin and Gaston, although confirming the necessity of a cofactor for the 'lupus inhibitor', showed that this cofactor was located in the gamma globulin fraction and therefore different from prothrombin. Almost 10 years later, Rivard and colleagues characterized the 'lupus cofactor' as a 200-kD plasma protein different from prothrombin or immunoglobulin, but with properties in common with each3.
Finally, in 1978 a paper was published in the British Journal of Haematology in which Exner and colleagues showed that the 'cofactor effect' might be attributable to traces of thrombin or platelet fragments in the test plasma4. It was more than a decade before a new cofactor came into focus.
At the 4th International Antiphospholipid Antibody Conference in Sirmione (Italy) in April 1990, three groups of researchers independently described a new cofactor, essential for the binding of anticardiolipin antibodies (aCL) to anionic phospholipids'-'. The crucial difference between this new cofactor and the so-called 'lupus ccaf~.~tor' is that the latter refers to a plasma component required for the expression of lupus anticoagulant, whereas the 'n~~' cofactor was shown to be involved in the interaction between aCL and lipids. The new cofactor was identified as 0,-glycoprotein I (J3z-GPI), also called apolipoprotein HS,6,8. This new finding explained why the use of 10Vo adult bovine serum improves the reliability of the solid-phase immunosorbent assay for antiphospholipid antibodies (aPL)9.
However, the absolute requirement of J32-GPI in the binding of aPL to phospholipids. has been questioned 10, 11.
The discovery of as a cofactor has initiated several studies and even actuated a special workshop on this subject12. In this issue of Lupus, two interesting papers by Sammaritano and co-workers (p. 83) and by Hunt and co-workers (p. 75) address the question of the role of J3z-GPI in the interaction of aCL with anionic phospholipids. First of all, a distinction should be made between patients with autoimmune disease and patients with infectious disease. As clearly demonstrated by Hunt and colleagues, infection-induced aCL can bind to anionic phospholipids in the absence of 027GPI, confirming earlier findings by Matsuura et al.7. In contrast, binding of aCL from patients with autoimmune disease is significantly enhanced by J}2-GPI, but this enhancement varies for different patients as well as for different subclasses of antibodies. Also, Sammaritano and co-workers show variability in the requirement for J}2-GPI for 20 different IgG and 12 different IgM aPL from non-infectious patients, but in all cases they found that the presence of J}2-GPI resulted in enhanced binding. In both papers, the authors underscore the importance of the purity of isolated immunoglobulins as well as the BSA preparation that is used to block non-specific binding in the solid-phase immunoassay. Indeed, we have found that isolation of aCL via protein A-Sepharose 4B affinity chromatography can result in an IgG preparation that seemingly does not require 02-GPI for binding to cardiolipin in a solid-phase assay (unpublished observation). However, aCL from the same patient isolated via liposome adsorption6 have an absolute requirement for J}2-GPI for binding to cardiolipin in the ELISA. Although Sammaritano and co-workers check their IgG and IgM preparations for contaminating 02-GPI by SDS-PAGE, it remains uncertain whether this technique is sufficiently sensitive to rule out a level of contamination that interferes with the ELISA. Therefore, it cannot be rigorously excluded that trace amounts of 0,-GPI contamination are responsible for the observed variability in the enhancement of aPL binding to cardiolipin by 'exogenous' J}2-GPI. A more sensitive radioimmunoassay is used by Hunt and co-workers to exclude ~,-GPI contamination in their immunoglobulin preparations. Nevertheless, their results also suggest that the requirement for J}2-GPI in the binding of aCL to lipids is not absolute. Variability in 0,-GPI dependency is found even for different subclasses of immunoglobulin within a single patient. Cofactor-dependent and cofactor-independent binding of aCL to has also been described my jSy-GPI is a well-characterized serum protein&dquo;&dquo; that can bind to negatively charged macromolecular structures other than phospholipids. These include DNA, phosphocellulose, heparin and deoxycholateI7-19.
J}2-GPI was shown to bind to human blood platelets, affecting ADP-induced aggregation20,21. Moreover, due to interaction with negatively charged surfaces, J}2-GPI interferes with blood coagulation by inhibiting the contact activation and the lipid-dependent activation of factor X and prothrombin22. 23. Taken together, these properties of J}2-GPI suggest that this protein could function as a natural circulating anticoagulant. We have recently obtained evidence that the inhibitory effect of J}2-GPI on the lipid-enhanced conversion of prothrombin by factors Xa/Va can be strongly potentiated by some, but not all, affinity-purified aCLI2. 02-GPI, however, does not complete the 'cofactor story'. It is well known that aPL include anticardiolipin as well as lupus anticoagulant (LA), and it has been demonstrated that in many cases these antibodies comprise different subgroups of immunoglobulins24,25. Isolated LA, separated from aCL, does not bind to anionic phospholipids even when ~3~-~I'I is present2l. This seems to be inconsistent with the notion that LA exerts its anticoagulant action through competition with coagulation factors for the lipid surface. However, we found that LA recognizes an epitope that becomes exposed upon calcium-mediated binding of human prothrombin to anionic phospholipids'. In other words, prothrombin could be considered as the counterpart of 02-GPI, being a cofactor for LA binding to lipids.
Taking together the involvement of 8,-GPI and prothrombin as 'cofactors' in the binding of aPL to anionic phospholipid surfaces, we propose a new hypothetical model for the generation of these antibodies in the antiphospholipid syndrome. The starting point is persistent endothelial cell damage and/or platelet activation resulting in increased exposure of procoagulant (read: anionic phospholipid) surfaces25. Plasma proteins such as {j2-GPI and prothrombin-Ca2+, which have a high affinity for anionic phospholipids, are relatively abundant (approximately 4 and 2.5 liM, respectively) and may bind to the lipid surface, thus exposing cryptic epitopes. Provided that the anionic phospholipid surface is exposed at a sufficiently high concentration for a sufficient period of time, the modified lipid-bound plasma proteins will evoke an immune response. The immune response, directed to modified plasma proteins rather than to lipids, therefor, be regarded as a consequence of the exposure of neo-antigens instead of as being caused by a disregulation of the immune system. This hypothesis does not exclude the idea that the #2-GPI-independent binding of some aCL generally observed in infectious diseases could involve other, as yet unidentified, protein cofactors. It may also offer an explanation for the frequently observed concurrence of aCL and LA in the antiphospholipid syndrome. Moreover, the thrombotic complications that often accompany this disease should then no longer be regarded as a consequence of high aPL titers, but merely as a reflection of a persistent exposure of anionic phospho-lipids. The primary cause for . the exposure of thrombogenic surfaces in patients with the antiphospholipid syndrome may become an important question for future research.
